Olendalizumab
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM) . Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus[1][2].
Product Specifications
CAS Number
[2210314-30-8]
Product Name Alternative
ALXN1007; Lendalizumab
UNSPSC
12352203
Target
Complement System
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/olendalizumab.html
Purity
98.32
Solubility
10 mM in DMSO
Smiles
[Olendalizumab]
Molecular Weight
(146 kDa)
References & Citations
[1]Dysinger M, et al. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma. AAPS J. 2018 Oct 2;20 (6) :106. |[2]Annane D, et al. Methods for treating a complement mediated disorder caused by viruses. World Intellectual Property Organization, WO2021211940 A1. 2021-10-21.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
